Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b, Dose-Escalation Study of the Safety and Preliminary Efficacy of STI-1386 Oncolytic Virus in Patients With Relapsed or Refractory Solid Tumors

NCT05361954 is registered in ClinicalTrials.gov with Sorrento Therapeutics, Inc. as lead sponsor.

NCT NCT05361954
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05361954 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b, Dose-Escalation Study of the Safety and Preliminary Efficacy of STI-1386 Oncolytic Virus in Patients With Relapsed or Refractory Solid Tumors
Lead sponsor
Sorrento Therapeutics, Inc.
Phase
Phase 1
Overall status
Not yet recruiting
Start date
August 31, 2023
Completion date
February 28, 2027
Enrollment
36 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

cancer, cancer of pancreas, hepatic metastasis, sarcoma, solid tumor